美股异动｜Vanda Pharmaceuticals大涨超26%，旗下晕动症药物获美国FDA批准

Core Viewpoint - Vanda Pharmaceuticals' stock surged over 26% to $8.9 following the FDA approval of its drug for preventing exercise-induced nausea, marking the first such approval in over 40 years [1] Company Summary - Vanda Pharmaceuticals announced the FDA approval of its drug named Nereus, which is designed to prevent exercise-induced vomiting [1] - The company plans to launch Nereus in the coming months [1] Industry Summary - The approval of Nereus represents a significant milestone in the pharmaceutical industry, as it is the first drug of its kind approved in over four decades [1]